Sign in
Taking people in SpainPhase 2

Tests low-dose aspirin in people with colon cancer, comparing those with and without obesity

Tests short courses of low-dose aspirin in adults with colorectal cancer, with and without obesity.

Key facts

Who runs it
Fundacion Instituto De Investigacion Sanitaria Aragon
Where
Zaragoza, SpainSee the site
Registry title
Effect of obesity due to the action of aspirin and its effectiveness in therapy for the treatment of colon cancer.
Status
Recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
5 Nov 2024
Planned end
1 May 2025
Type of study
Interventional
Record updated
5 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent colon or rectal cancer diagnosis. It compares obese and non-obese patients taking low-dose aspirin for one week.

Age
From 18 years up to under 80 years.
Sex
Men and women can join.
Disease stage
Recent diagnosis of colon or rectal cancer, confirmed by endoscopy and a tissue study.
Earlier treatment
Cannot have used aspirin, NSAIDs, antiplatelet drugs, corticosteroids or misoprostol in the 15 days before diagnosis. Rectal cancer needing neoadjuvant treatment within three weeks of starting aspirin is excluded.
Biomarker or test result
Normal blood clotting tests. Obese group: BMI 30 or higher. Non-obese group: BMI 25 or lower.

Main reasons for not taking part

  • Allergy to aspirin, other salicylates, NSAIDs or tartrazine
  • Bleeding or clotting disorders, such as hemophilia
  • History of stomach ulcer or other stomach or gut disease that rules out aspirin, without proton pump inhibitors
  • Another cancer (not non-melanoma skin cancer) in the previous 3 years
  • Active smoking, pregnancy or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 18 years and < 80 years
  • Recent diagnosis (colon or rectal cancer, established by endoscopy and subsequently confirmed by anatomo-pathological study)
  • Coagulation study within the normal range and usual biochemical parameters without clinically significant deviations that, in the opinion of the investigator, could interfere with the study procedures
  • In the obese group, patients with BMI ≥ 30 will be selected. In the non-obese group, patients with BMI ≤ 25 will be selected

Who cannot take part

  • Treatment with methotrexate at doses of 15 mg/week or higher
  • Rectal cancer requiring neoadjuvant treatment within three weeks of starting treatment with ASA
  • Previous use of ASA, NSAIDs, antiplatelet agents, corticosteroids or misoprostol in the 15 days prior to diagnosis and/or anticipated need for treatment with any of these drugs during the study period
  • History of peptic ulcer or active peptic ulcer or any other GI disease that may be considered a contraindication to the use of ASA, without concomitant use of proton pump inhibitors
  • Diagnosis of bleeding disorders or gastric perforation after treatment with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs
  • Diagnosis of cancer (excluding non-melanoma skin cancer) in the previous 3 years
  • Allergy to ASA or other salicylates, non-steroidal anti-inflammatory drugs or tartrazine (cross-reaction) or any of the excipients. Allergy to other salicylates, non-steroidal anti-inflammatory drugs or tartrazine (cross-reaction) or any of the excipients
  • History of drug use or alcohol abuse
  • Diseases with coagulation disorders, mainly hemophilia or hypoprothrombinemia
  • Conditions involving serious comorbidity, excluding diabetes and including respiratory, cardiac, liver and kidney diseases
  • Patients with nasal polyps associated with asthma that are induced or exacerbated by acetylsalicylic acid
  • Active smoking
  • Pregnancy or breastfeeding status

Where in Spain

  • Hospital Clinico Universitario Lozano BlesaZaragoza, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the effect of a short course (one week) of enteric-coated acetylsalicylic acid at low doses (100 mg/24h) on platelet COX-1 and COX-2 in patients diagnosed with colorectal cancer (CRC), comparing these effects in obese and non-obese patients. And evaluate the effects of another short course (one week) of different doses of acetylsalicylic acid (300 mg/day, 100 mg/12h or maintain 100 mg/24 hours) on COX-1 and COX-2 in platelets, healthy colonic tissue and tumor in patients diagnosed with CRC comparing these effects in obese and non-obese patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Effect of obesity on the acetylation of COX1 and COX2 by aspirin as a biomarker of its effectiveness in chemoprevention and therapy in colon cancer: A Phase II Clinical Trial
Plain-language title
Tests low-dose aspirin in people with colon cancer, comparing those with and without obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2024